Pub Date : 2025-12-06DOI: 10.1053/j.ajkd.2025.09.019
Waleed Zafar MD, Yirui Hu PhD, Lauren Brubaker MPH, Nathaniel Harshaw BS, Jamie Green MD MS, Alexander R. Chang MD MS
Early detection of albuminuria can enable administration of therapeutic interventions that improve clinical outcomes in patients at elevated risk for chronic kidney disease (CKD). We investigated the impact of smartphone-enabled home urinary albumin-to-creatinine ratio (UACR) testing on albuminuria screening and clinical management of these patients.
{"title":"Impact of Smartphone-Enabled Home Urinary Albumin-to-Creatinine Ratio Testing on Albuminuria Screening and Management","authors":"Waleed Zafar MD, Yirui Hu PhD, Lauren Brubaker MPH, Nathaniel Harshaw BS, Jamie Green MD MS, Alexander R. Chang MD MS","doi":"10.1053/j.ajkd.2025.09.019","DOIUrl":"https://doi.org/10.1053/j.ajkd.2025.09.019","url":null,"abstract":"Early detection of albuminuria can enable administration of therapeutic interventions that improve clinical outcomes in patients at elevated risk for chronic kidney disease (CKD). We investigated the impact of smartphone-enabled home urinary albumin-to-creatinine ratio (UACR) testing on albuminuria screening and clinical management of these patients.","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"110 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145697285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-05DOI: 10.1053/j.ajkd.2025.09.018
Chloe Wong-Mersereau,Saly El Wazze,Kathleen Gaudio,Katya Loban,Shaifali Sandal
RATIONALE & OBJECTIVELiving kidney donors (LKDs) perceive gaps in care along their donation journeys, such as poor coordination and communication between providers. Better integration of their primary care providers (PCPs) in their donation journey can help address these gaps. We sought to capture the perspectives of Canadian PCPs to understand the challenges they perceive when caring for LKDs and their recommendations to address them.STUDY DESIGNQualitative descriptive design.SETTING & PARTICIPANTSSemi-structured in-depth interviews with 19 family physicians conducted until data saturation.ANALYTICAL APPROACHThematic analysis.RESULTSParticipants highlighted several challenges with the current living kidney donation processes: 1) Limited scope of LKD care in primary practice; 2) Poor clarity surrounding roles and responsibilities pre-donation (perceived as a facilitator) and post-donation (perceived as low-barrier and high-access resource, and providing soft psychosocial support); 3) Variable understanding of the living kidney donation process; and 4) Lack of support and resources (patient accessibility to primary care, communication challenges between providers, poor health record transmission, limited availability of mental health services, limited financial support for patients and providers). Participants had three key recommendations: 1) Support PCPs with pragmatic approaches and on-demand resources; 2) Empower LKDs to be active participants in their care; and 3) Implement strategies to address LKD care provision deficiencies (primary care accessibility, developing a collaborative care model, improving communication between all stakeholders, dedicated and prolonged psychosocial support, and governmental prioritization).LIMITATIONSAbout half the sample had limited experience with LKD care; inability to recruit some PCPs such as nurse practitioners.CONCLUSIONSAs co-providers of patient care during the pre-donation phase and the primary drivers of care in the post-donation period, PCPs are positioned to deliver high-quality care to LKDs, contribute to long-term data collection, and potentially improve LKD outcomes. This study outlines challenges PCPs perceive and possible approaches to address them.
{"title":"Family Physicians' Perspectives on Providing Living Kidney Donor Care.","authors":"Chloe Wong-Mersereau,Saly El Wazze,Kathleen Gaudio,Katya Loban,Shaifali Sandal","doi":"10.1053/j.ajkd.2025.09.018","DOIUrl":"https://doi.org/10.1053/j.ajkd.2025.09.018","url":null,"abstract":"RATIONALE & OBJECTIVELiving kidney donors (LKDs) perceive gaps in care along their donation journeys, such as poor coordination and communication between providers. Better integration of their primary care providers (PCPs) in their donation journey can help address these gaps. We sought to capture the perspectives of Canadian PCPs to understand the challenges they perceive when caring for LKDs and their recommendations to address them.STUDY DESIGNQualitative descriptive design.SETTING & PARTICIPANTSSemi-structured in-depth interviews with 19 family physicians conducted until data saturation.ANALYTICAL APPROACHThematic analysis.RESULTSParticipants highlighted several challenges with the current living kidney donation processes: 1) Limited scope of LKD care in primary practice; 2) Poor clarity surrounding roles and responsibilities pre-donation (perceived as a facilitator) and post-donation (perceived as low-barrier and high-access resource, and providing soft psychosocial support); 3) Variable understanding of the living kidney donation process; and 4) Lack of support and resources (patient accessibility to primary care, communication challenges between providers, poor health record transmission, limited availability of mental health services, limited financial support for patients and providers). Participants had three key recommendations: 1) Support PCPs with pragmatic approaches and on-demand resources; 2) Empower LKDs to be active participants in their care; and 3) Implement strategies to address LKD care provision deficiencies (primary care accessibility, developing a collaborative care model, improving communication between all stakeholders, dedicated and prolonged psychosocial support, and governmental prioritization).LIMITATIONSAbout half the sample had limited experience with LKD care; inability to recruit some PCPs such as nurse practitioners.CONCLUSIONSAs co-providers of patient care during the pre-donation phase and the primary drivers of care in the post-donation period, PCPs are positioned to deliver high-quality care to LKDs, contribute to long-term data collection, and potentially improve LKD outcomes. This study outlines challenges PCPs perceive and possible approaches to address them.","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"115 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-05DOI: 10.1053/j.ajkd.2025.10.012
Esmee Driehuis,Sanne C E Peters,Anneke J Roeterdink,Theodôr J F M Vogels,Namiko A Goto,Marjolein I Broese van Groenou,Renée de Wildt,Friedo W Dekker,Brigit C van Jaarsveld,Alferso C Abrahams
RATIONALE & OBJECTIVEStarting dialysis is challenging for both patients and their informal caregivers. Caregivers help patients adapt and adhere to treatment by providing practical and emotional support, but these responsibilities can take a considerable toll on them. As little is known about how caregiver experiences evolve after dialysis initiation, we aimed to: 1) assess the trajectory of experiences and health-related quality of life (HRQoL) of caregivers of patients on dialysis during the first year of dialysis, 2) assess whether differences in these trajectories exist between caregivers of home dialysis patients and those of in-center hemodialysis (ICHD) patients, and 3) explore in which domains caregivers desire support over time.STUDY DESIGNMulticenter, longitudinal cohort study.SETTING & PARTICIPANTS202 dyads of incident dialysis patients and their adult informal caregivers.EXPOSUREHome dialysis and ICHD.OUTCOMESPositive experiences, caregiver burden, depressive symptoms, and HRQoL.ANALYTICAL APPROACHDescriptive analyses of desired support and linear mixed models to assess and compare trajectories.RESULTSAll but two of the caregiver outcomes deteriorated over the first year of dialysis. The change over time (β, 95%CI) was significant for positive experiences (-1.44, -2.36; -0.51), depressive symptoms (5.20, 3.15; 7.25), physical HRQoL (-5.73, -9.20; -2.26), general HRQoL (-0.13, -0.17; -0.07) and perceived health status (-9.40, -15.12; -3.67), but not for caregiver burden (0.85, -0.02; 1.72) or mental HRQoL (-2.99, -6.93; 0.94). No differences in the trajectories were found between caregivers of patients receiving home dialysis and ICHD, but these groups did differ in desired support.LIMITATIONSSmall sample size of subgroups.CONCLUSIONSInformal caregivers experience significant challenges during the first year of dialysis, marked by a notable decline in positive experiences, physical and general HRQoL, and perceived health status, alongside an increase in depressive symptoms, regardless of dialysis location. These findings underscore the need for targeted support for informal caregivers in dialysis care.
{"title":"Trajectories of Experiences and Health-Related Quality of Life of Informal Caregivers of Home and In-Center Dialysis Patients: A Multicenter Longitudinal Cohort Study.","authors":"Esmee Driehuis,Sanne C E Peters,Anneke J Roeterdink,Theodôr J F M Vogels,Namiko A Goto,Marjolein I Broese van Groenou,Renée de Wildt,Friedo W Dekker,Brigit C van Jaarsveld,Alferso C Abrahams","doi":"10.1053/j.ajkd.2025.10.012","DOIUrl":"https://doi.org/10.1053/j.ajkd.2025.10.012","url":null,"abstract":"RATIONALE & OBJECTIVEStarting dialysis is challenging for both patients and their informal caregivers. Caregivers help patients adapt and adhere to treatment by providing practical and emotional support, but these responsibilities can take a considerable toll on them. As little is known about how caregiver experiences evolve after dialysis initiation, we aimed to: 1) assess the trajectory of experiences and health-related quality of life (HRQoL) of caregivers of patients on dialysis during the first year of dialysis, 2) assess whether differences in these trajectories exist between caregivers of home dialysis patients and those of in-center hemodialysis (ICHD) patients, and 3) explore in which domains caregivers desire support over time.STUDY DESIGNMulticenter, longitudinal cohort study.SETTING & PARTICIPANTS202 dyads of incident dialysis patients and their adult informal caregivers.EXPOSUREHome dialysis and ICHD.OUTCOMESPositive experiences, caregiver burden, depressive symptoms, and HRQoL.ANALYTICAL APPROACHDescriptive analyses of desired support and linear mixed models to assess and compare trajectories.RESULTSAll but two of the caregiver outcomes deteriorated over the first year of dialysis. The change over time (β, 95%CI) was significant for positive experiences (-1.44, -2.36; -0.51), depressive symptoms (5.20, 3.15; 7.25), physical HRQoL (-5.73, -9.20; -2.26), general HRQoL (-0.13, -0.17; -0.07) and perceived health status (-9.40, -15.12; -3.67), but not for caregiver burden (0.85, -0.02; 1.72) or mental HRQoL (-2.99, -6.93; 0.94). No differences in the trajectories were found between caregivers of patients receiving home dialysis and ICHD, but these groups did differ in desired support.LIMITATIONSSmall sample size of subgroups.CONCLUSIONSInformal caregivers experience significant challenges during the first year of dialysis, marked by a notable decline in positive experiences, physical and general HRQoL, and perceived health status, alongside an increase in depressive symptoms, regardless of dialysis location. These findings underscore the need for targeted support for informal caregivers in dialysis care.","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"55 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-05DOI: 10.1053/j.ajkd.2025.10.010
Katherine A. Barraclough PhD , Ben Talbot PhD , Scott McAlister PhD
{"title":"In Reply to “Low-Flow Home Hemodialysis Technologies: The Key to Greener Dialysis?”","authors":"Katherine A. Barraclough PhD , Ben Talbot PhD , Scott McAlister PhD","doi":"10.1053/j.ajkd.2025.10.010","DOIUrl":"10.1053/j.ajkd.2025.10.010","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 284-285"},"PeriodicalIF":8.2,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1053/j.ajkd.2025.07.022
Patrizia Natale , Suetonia C. Green , Jonathan C. Craig , Giovanni F.M. Strippoli
{"title":"Blood Pressure–Lowering Agents for Kidney Transplant Recipients: Editorial Summary of a Cochrane Review","authors":"Patrizia Natale , Suetonia C. Green , Jonathan C. Craig , Giovanni F.M. Strippoli","doi":"10.1053/j.ajkd.2025.07.022","DOIUrl":"10.1053/j.ajkd.2025.07.022","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 270-272"},"PeriodicalIF":8.2,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1053/j.ajkd.2025.10.009
Wolfgang C Winkelmayer,Kevin F Erickson,Pascale Khairallah,Mingyue He,Maria E Montez-Rath,Tara I Chang,Jingbo Niu
RATIONALE & OBJECTIVEAtrial fibrillation (AF) is common among patients with kidney failure on hemodialysis (KFHD). We studied the outcomes of apixaban initiation, compared with no initiation of any oral anticoagulation (OAC), among patients with KFHD and newly-diagnosed AF.STUDY DESIGNRetrospective cohort study.SETTING & PARTICIPANTSMedicare-insured patients with KFHD, with newly-diagnosed AF, and without recent OAC use (2014-2019).EXPOSUREInitiation of apixaban treatment versus no OAC initiation within 30 days of an AF diagnosis.OUTCOMESThromboembolic and bleeding events and death within 365 days of follow-up.ANALYTICAL APPROACHPropensity-matched comparison of new apixaban users and OAC non-users implemented using Cox proportional hazards models while accounting for competing risks.RESULTSWithin 30 days of the new diagnosis of AF among 63,300 previously OAC-naïve patients, 4010 initiated apixaban and 59,290 did not initiate any OAC within 30 days. After propensity matching, 3985 apixaban users were well-matched to 3985 OAC non-users on all measured characteristics. Median CHA2DS2-VASc, a multidimensional stroke risk score, was 4 (IQR: 3-5). Apixaban was initiated a median 5 (IQR: 2-12) days after AF and used for a median 59 (IQR: 37-135) days. In intention-to-treat analyses, rates of ischemic stroke were 25% lower (HR=0.75; 95%CI, 0.57-0.97) and those of a composite outcome of thromboembolic events and cardiovascular death were 24% lower (HR=0.76; 95%CI, 0.70-0.83) among apixaban users. Conversely, apixaban users had a 55% higher rate of hemorrhagic stroke (HR=1.55; 95%CI, 1.03-2.33) and a 29% increased rate of clinically important bleeding (HR=1.29; 95%CI, 1.14-1.45). The HR for all-cause mortality was 0.61 (95%CI, 0.56-0.67). Results from as-treated analyses were qualitatively consistent with intent-to-treat analyses, but generally larger in magnitude.LIMITATIONSPotential for residual confounding from unobserved characteristics or informative censoring unaccounted for by competing risk models.CONCLUSIONSAmong patients with KFHD, initiation of apixaban soon after newly-diagnosed AF, compared to no anticoagulation, was associated with lower risks of ischemic stroke, a composite thromboembolic endpoint, and all-cause mortality, but higher rates of clinically meaningful bleeding.
{"title":"Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis.","authors":"Wolfgang C Winkelmayer,Kevin F Erickson,Pascale Khairallah,Mingyue He,Maria E Montez-Rath,Tara I Chang,Jingbo Niu","doi":"10.1053/j.ajkd.2025.10.009","DOIUrl":"https://doi.org/10.1053/j.ajkd.2025.10.009","url":null,"abstract":"RATIONALE & OBJECTIVEAtrial fibrillation (AF) is common among patients with kidney failure on hemodialysis (KFHD). We studied the outcomes of apixaban initiation, compared with no initiation of any oral anticoagulation (OAC), among patients with KFHD and newly-diagnosed AF.STUDY DESIGNRetrospective cohort study.SETTING & PARTICIPANTSMedicare-insured patients with KFHD, with newly-diagnosed AF, and without recent OAC use (2014-2019).EXPOSUREInitiation of apixaban treatment versus no OAC initiation within 30 days of an AF diagnosis.OUTCOMESThromboembolic and bleeding events and death within 365 days of follow-up.ANALYTICAL APPROACHPropensity-matched comparison of new apixaban users and OAC non-users implemented using Cox proportional hazards models while accounting for competing risks.RESULTSWithin 30 days of the new diagnosis of AF among 63,300 previously OAC-naïve patients, 4010 initiated apixaban and 59,290 did not initiate any OAC within 30 days. After propensity matching, 3985 apixaban users were well-matched to 3985 OAC non-users on all measured characteristics. Median CHA2DS2-VASc, a multidimensional stroke risk score, was 4 (IQR: 3-5). Apixaban was initiated a median 5 (IQR: 2-12) days after AF and used for a median 59 (IQR: 37-135) days. In intention-to-treat analyses, rates of ischemic stroke were 25% lower (HR=0.75; 95%CI, 0.57-0.97) and those of a composite outcome of thromboembolic events and cardiovascular death were 24% lower (HR=0.76; 95%CI, 0.70-0.83) among apixaban users. Conversely, apixaban users had a 55% higher rate of hemorrhagic stroke (HR=1.55; 95%CI, 1.03-2.33) and a 29% increased rate of clinically important bleeding (HR=1.29; 95%CI, 1.14-1.45). The HR for all-cause mortality was 0.61 (95%CI, 0.56-0.67). Results from as-treated analyses were qualitatively consistent with intent-to-treat analyses, but generally larger in magnitude.LIMITATIONSPotential for residual confounding from unobserved characteristics or informative censoring unaccounted for by competing risk models.CONCLUSIONSAmong patients with KFHD, initiation of apixaban soon after newly-diagnosed AF, compared to no anticoagulation, was associated with lower risks of ischemic stroke, a composite thromboembolic endpoint, and all-cause mortality, but higher rates of clinically meaningful bleeding.","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"1 1","pages":""},"PeriodicalIF":13.2,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1053/j.ajkd.2025.09.017
Daan P.C. van Doorn , Salwan Al-Nasiry , Marc E.A. Spaanderman , Jan G.M.C. Damoiseaux , Pieter van Paassen , Sjoerd A.M.E.G. Timmermans
Thrombotic microangiopathies (TMAs) are severe endotheliopathies that can arise in pregnancy and require early recognition. Complement-mediated (C-)TMA should be differentiated from other endotheliopathies of pregnancy because the treatment differs. Here, we report a case of a pregnant woman with acute kidney injury requiring hemodialysis due to C-TMA on the background of a pathogenic C3 variant at 28+5 weeks of gestation. The low soluble Fms-like tyrosine kinase-1 to placental growth factor (sFlt1/PlGF) ratio excluded pre-eclampsia. Eculizumab was started, and therapeutic drug monitoring was applied for optimal dosing. Despite prolonged hemodialysis, fetal well-being was preserved, and delivery was safely postponed till 34+3 weeks of gestation, resulting in a healthy neonate. We also separately report on sFlt1/PlGF ratios measured in a cohort of 11 patients with TMA and coexisting pregnancy. Ten of 11 patients (91%) had low sFlt1/PlGF ratios, excluding pre-eclampsia. Thus, successful pregnancy in women with C-TMA can occur, and sFlt1/PlGF ratios may aid in clarifying the diagnosis and appropriate treatment.
{"title":"Thrombotic Microangiopathy During Pregnancy: Role of Soluble Fms-like Tyrosine Kinase-1–Placental Growth Factor Ratios","authors":"Daan P.C. van Doorn , Salwan Al-Nasiry , Marc E.A. Spaanderman , Jan G.M.C. Damoiseaux , Pieter van Paassen , Sjoerd A.M.E.G. Timmermans","doi":"10.1053/j.ajkd.2025.09.017","DOIUrl":"10.1053/j.ajkd.2025.09.017","url":null,"abstract":"<div><div>Thrombotic microangiopathies (TMAs) are severe endotheliopathies that can arise in pregnancy and require early recognition. Complement-mediated (C-)TMA should be differentiated from other endotheliopathies of pregnancy because the treatment differs. Here, we report a case of a pregnant woman with acute kidney injury requiring hemodialysis due to C-TMA on the background of a pathogenic <em>C3</em> variant at 28+5 weeks of gestation. The low soluble Fms-like tyrosine kinase-1 to placental growth factor (sFlt1/PlGF) ratio excluded pre-eclampsia. Eculizumab was started, and therapeutic drug monitoring was applied for optimal dosing. Despite prolonged hemodialysis, fetal well-being was preserved, and delivery was safely postponed till 34+3 weeks of gestation, resulting in a healthy neonate. We also separately report on sFlt1/PlGF ratios measured in a cohort of 11 patients with TMA and coexisting pregnancy. Ten of 11 patients (91%) had low sFlt1/PlGF ratios, excluding pre-eclampsia. Thus, successful pregnancy in women with C-TMA can occur, and sFlt1/PlGF ratios may aid in clarifying the diagnosis and appropriate treatment.</div></div>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 278-283"},"PeriodicalIF":8.2,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-29DOI: 10.1053/j.ajkd.2025.10.008
Georgina Gyarmati
{"title":"Are Mother Glomeruli in Good or Bad Company?","authors":"Georgina Gyarmati","doi":"10.1053/j.ajkd.2025.10.008","DOIUrl":"10.1053/j.ajkd.2025.10.008","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 275-277"},"PeriodicalIF":8.2,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：